U.S. Markets close in 1 hr 46 mins
  • S&P 500

    4,566.93
    +22.03 (+0.48%)
     
  • Dow 30

    35,741.03
    +64.01 (+0.18%)
     
  • Nasdaq

    15,229.81
    +139.61 (+0.93%)
     
  • Russell 2000

    2,312.14
    +20.88 (+0.91%)
     
  • Gold

    1,808.50
    +12.20 (+0.68%)
     
  • EUR/USD

    1.1618
    -0.0027 (-0.2324%)
     
  • 10-Yr Bond

    1.6370
    -0.0180 (-1.09%)
     
  • Vix

    15.24
    -0.19 (-1.23%)
     
  • GBP/USD

    1.3773
    +0.0014 (+0.1005%)
     
  • USD/JPY

    113.6610
    +0.2010 (+0.1772%)
     
  • BTC-USD

    62,967.34
    +2,818.43 (+4.69%)
     
  • CMC Crypto 200

    1,505.39
    +1,262.71 (+520.32%)
     
  • FTSE 100

    7,222.82
    +18.27 (+0.25%)
     
  • Nikkei 225

    28,600.41
    -204.44 (-0.71%)
     

Swelling losses haven't held back gains for Inovio Pharmaceuticals (NASDAQ:INO) shareholders since they're up 56% over 3 years

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) shareholders might be concerned after seeing the share price drop 20% in the last week. In contrast the stock is up over the last three years. Arguably you'd have been better off buying an index fund, because the gain of 56% in three years isn't amazing.

While this past week has detracted from the company's three-year return, let's look at the recent trends of the underlying business and see if the gains have been in alignment.

Check out our latest analysis for Inovio Pharmaceuticals

Because Inovio Pharmaceuticals made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

Inovio Pharmaceuticals actually saw its revenue drop by 83% per year over three years. The revenue growth might be lacking but the share price has gained 16% each year in that time. Unless the company is going to make profits soon, we would be pretty cautious about it.

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

earnings-and-revenue-growth
earnings-and-revenue-growth

Take a more thorough look at Inovio Pharmaceuticals' financial health with this free report on its balance sheet.

A Different Perspective

While the broader market gained around 32% in the last year, Inovio Pharmaceuticals shareholders lost 48%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 2% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 2 warning signs for Inovio Pharmaceuticals you should know about.

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.